<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02921243</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00069555</org_study_id>
    <nct_id>NCT02921243</nct_id>
  </id_info>
  <brief_title>Schizophrenia and the Gut Microbiome</brief_title>
  <official_title>Schizophrenia and the Gut Microbiome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a sample of 20 inpatients with a DSM-IV-TR/DSM 5 diagnosis of schizophrenia or
      schizoaffective disorder, investigators propose to conduct a prospective, 2 week
      observational trial to collect gastrointestinal stool samples in order to characterize the
      microbiota in people with schizophrenia and examine its variability over time. Participants
      may elect to participate for an additional two weeks, during which they will receive the
      prebiotic, oligofructose-enriched inulin (FOS), in order to examine its effects on the
      relative preponderance of butyrate-producing bacteria in the gut microbiome. Investigators
      will use an inpatient sample in order to standardize meals, exercise and environmental
      mediators. This is considered a feasibility, pilot study in order to apply for future grant
      funding. Investigators will recruit patients from the Treatment Research Program inpatient
      unit, Maryland Psychiatric Research Center, University of Maryland School of Medicine.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>16S rRNA gene amplicons from stool samples</measure>
    <time_frame>4 weeks</time_frame>
    <description>The 16S rRNA gene amplicon data will be used to examine the relative preponderance of butyrate-producing bacteria in the gut microbiota of people with schizophrenia.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>Stool Sample Collection</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Prebiotic</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Metatranscriptomics: Metatranscriptomics analyses provide a snapshot of the expressed genes
      in a sample, which allows for mechanistic insights into the microbiome not possible with 16S
      rRNA profiling only.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        In-participants with Schizophrenia
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. DSM-IV-TR /DSM 5 diagnosis of schizophrenia or schizoaffective disorder;

          2. Age 18-64 years;

          3. currently hospitalized for at least 7 days

          4. currently treated with an antipsychotic, with no dose changes in last 14 days

          5. ability to participate in the informed consent process, as determined by a score of 10
             or greater on the Evaluation to Sign Consent

        Exclusion Criteria:

          1. Gastrointestinal disorders, including, but not limited to Crohn's Disease, Irritable
             Bowel Syndrome, Celiac Disease,

          2. Organic brain disorder, including cerebrovascular accident; epilepsy; traumatic brain
             injury, Loss of consciousness (LOC) for more than 30 minutes

          3. Mental retardation

          4. Antibiotic or immune therapy within the last three months

          5. Prebiotic or probiotic treatment within the last three months

          6. Inability to understand English

          7. Inability to cooperate with study procedures

          8. Pregnant women

          9. Prisoner status

         10. For MRI ONLY Contraindication for MRI scanning (e.g. metal in body, pacemaker).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ann Kearns, MS</last_name>
    <phone>410-402-6854</phone>
    <email>akearns@mprc.umaryland.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephanie Feldman, MSW</last_name>
    <phone>410-402-6885</phone>
    <email>sfeldman@mprc.umaryland.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maryland Psychiatric Research Center</name>
      <address>
        <city>Catonsville</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Kearns, BS</last_name>
      <phone>410-402-6854</phone>
      <email>akearns@mprc.umaryland.edu</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Feldman, LCSW</last_name>
      <phone>410-402-6885</phone>
      <email>sfeldman@mprc.umaryland.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Deanna L. Kelly, Pharm.D., BCPP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mprc.umaryland.edu</url>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2016</study_first_submitted>
  <study_first_submitted_qc>September 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2016</study_first_posted>
  <last_update_submitted>November 13, 2017</last_update_submitted>
  <last_update_submitted_qc>November 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland</investigator_affiliation>
    <investigator_full_name>Robert W. Buchanan</investigator_full_name>
    <investigator_title>Director, Maryland Psychiatric Research Cente</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

